CDC-RFA-GH-23-0042: Global Emergency Response and Recovery Partner Engagement: Expanding Efforts and Strategies to Improve Rapid Response to Public Health Emergencies Globally
Closed
This grant is closed. A newer notice from the same program is forecast: Capacity Building for National Immunization Programs in the Eastern Mediterranean Region (CDC-RFA-JG-27-0070). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control - CGH notices from 2023.
Centers for Disease Control - CGH offered grants to any type of organization. It expected to make about 10 awards worth $25.0 million in total. Applications closed on June 6, 2023.
From the official notice on Grants.gov, last changed May 11, 2023. Checked November 7, 2026.
- Total funding$25.0 million
- Expected awards10
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | April 5, 2023 |
|---|---|
| Deadline | June 6, 2023 |
| Archived by Grants.gov | June 30, 2028 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
CDC may reopen this announcement periodically over the 5-year NOFO period to accommodate evolving public health emergency and/or humanitarian crisis response needs and ensure we maintain a current roster of all eligible applicants for emergency response geographically. The anticipated dates for re-posting are noted below. Applicants will have 60 days following re-posting to submit an application. April 2024April 2025April 2026April 2027
Is this a realistic fit?
- Most of the program's money (49% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
This NOFO supports the implementation of programs and activities targeted at increasing the capacity of public health emergency partners to rapidly respond to support populations affected by humanitarian emergencies and conflict settings. Its purpose is to improve the ability to detect and respond to threats early and develop long-term, sustainable programs to rebuild resilience during and after an emergency. This NOFO will establish an Approved-But-Unfunded (ABU) list of recipients, providing a portfolio of partners that can work anywhere in the world. CDC will fund partners to respond to emergencies that require federal support to effectively respond to, manage, and address identified public health threats.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before
From fiscal 2021 to 2025, Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security (93.318) awarded $1.3 billion across 306 grant awards, an average of $4.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| African Field Epidemiology Network LTD | 6 | $147 million | |
| The Task Force for Global Health, Inc. | Georgia | 7 | $138 million |
| World Health Organization, Somalia | 14 | $125 million | |
| Association of Public Health Laboratories, Inc. (the) | Maryland | 3 | $61.5 million |
| The Johns Hopkins University | Maryland | 5 | $42.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0070, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-GH-23-0042 still open?
No. It closed on June 6, 2023. A newer notice is forecast: CDC-RFA-JG-27-0070, expected deadline February 12, 2027.
Who can apply for Global Emergency Response and Recovery Partner Engagement: Expanding Efforts and Strategies to Improve Rapid Response to Public Health Emergencies Globally?
Centers for Disease Control - CGH accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Global Emergency Response and Recovery Partner Engagement: Expanding Efforts and Strategies to Improve Rapid Response to Public Health Emergencies Globally?
Closed June 6, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $25.0 million in total across about 10 awards.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before?
The largest recipients over five fiscal years were African Field Epidemiology Network LTD, The Task Force for Global Health, Inc., World Health Organization, Somalia. The program made 306 awards worth $1.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)